A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing
The order this company entered each market — oldest to newest
Sign up to see the full signal feed
How WuXi Vaccines's international expansion compares to its competitors
WuXi VaccinesYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 WuXi VaccinesYou | 0 | 0 | 0% | 0 | 28 |
Process Development Scientist - Senior Scientist - Principal Scientist
View postingSuzhou, Jiangsu, China · 12mo ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
WuXi Vaccines' Suzhou facility (DP17) received GMP certification from ANVISA for Butantan Institute's dengue vaccine production, marking a significant regulatory milestone.
WuXi Vaccines' Suzhou facility received GMP certification from Brazil's ANVISA for dengue vaccine production with Instituto Butantan.
WuXi Vaccines' Suzhou facility received ANVISA GMP certification for dengue vaccine production with Instituto Butantan, enabling end-to-end manufacturing of tens of millions of doses for Brazil.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about WuXi Vaccines's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
